ACG clinical guideline: The diagnosis and management of idiosyncratic drug-induced liver injury

American Journal of Gastroenterology

Volumn 109, Issue 7, 2014, Pages 950-966

  Chalasani, Naga P ^a   Hayashi, Paul H ^b   Bonkovsky, Herbert L ^c   Navarro, Victor J ^d   Lee, William M ^e   Fontana, Robert J ^f  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c LEVINE CANCER INSTITUTE   (United States)

^d Einstein Healthcare Network   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD EXAMINATION; DIAGNOSTIC IMAGING; DIET SUPPLEMENTATION; EVIDENCE BASED PRACTICE; HUMAN; LIVER BIOPSY; MEDICAL HISTORY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TOXIC HEPATITIS;

ANIMALS; DIETARY SUPPLEMENTS; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PLANT PREPARATIONS; RISK FACTORS;

EID: 84903897064     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.131     Document Type: Review

References (99)

1. Guyatt GH, Oxman AD, Vist GE et al. GRADE:an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
2. Bonkovsky HL, Jones DP, Russo MW et al. Drug-Induced Liver Injury. 6th edn. Ch 25 W.B. Saunders: Philadelphia, PA, 2011, pp. 417-61.
3. Strader DB, Navarro VJ, Seef LB. Hepatotoxicity from herbal preparation. In: Boyer TD, Mann M, Sanyal AJ (eds). Zakim & Boyer's Hepatology, 6th edn. Ch 26 W.B. Saunders: Philadelphia, PA, 2011, pp. 462-75.
4. Lewis JH. Drug-induced liver injury throughout the drug development life cycle: where we have been, where are we now, and where we are headed. Perspectives of a clinical hepatologist. Pharm Med 2013;27: 165-91.
5. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005;4:489-99.
6. Kaplowitz N, DeLeve LD. Drug-Induced Liver Disease, 3rd edn, Academic press: Waltham, MA, 2013.
7. Andrade RJ, Lucena MI, Fernandez MC et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512-21.
8. Bjornsson E, Bergmann OM, Bjornsson HK et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25.
9. Tujios S, Fontana RJ. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol 2011;8:202-11.
10. Russo M, Galanko JA, Shrestha R et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004;10:1018-23.
11. Larson AM, Fontana RJ, Davern TJ, et al., the ALFSG. Acetaminophen- induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005;42:1367-72.
12. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006;15:241-3.
13. Rivkees SA. 63 Years and 715 days to the " boxed warning ": unmasking of the propylthiouracil problem. Int J Pediatr Endocrinol 2010;2010, Pii:717303.
14. Koch L. T erapy: propylthiouracil use associated with severe hepatotoxicity in children. Nat Rev Endocrinol 2010;6:416 Chalasani 20 (Fatal PTU).
15. Vuppalanchi R, Chalasani N. Risk factors for drug-induced liver disease. In: Kaplowitz N and DeLeve LD (eds) Drug-Induced Liver Disease, 3rd edn, Academic press: Waltham, MA, 2013, pp. 265-74.
16. Chalasani N, Fontana RJ, Bonkovsky HL et al. Causes, clinical features, and outcomes from a prospective study of drug induced liver injury in the United States. Gastroenterology 2008;135:1924-34.
17. Danan G, Benichou C. C au sality assessm en t o f ad verse reactio n s to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-30.
18. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331-6.
19. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26:664-9.
20. Agarwal VK, McHutchison JG, Hoofnagle JH. Im p o rtan t elem en ts fo r the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010;8:463-70.
21. Navarro VJ, Barnhart HX, Bonkovsky HL et al. Herbal and dietary supplement induced hepatotoxicity in the US. Gastroenterology 2012;142 S1, S-41. [Abstract #167].
22. Http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/ SummaryofNDAApprovalsReceipts1938tothepresent/default.htm (Accessed on 15 October 2013).
23. !http://livertox.nih.gov/ (Accessed on 15 October 2013).
24. Davern TJ, Chalasani N, Fontana RJ et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastro-enterology 2011;141:1665-72 e1-9.
25. Hoofnagle JH, Nelson KE, Purcell RH. H ep atitis E. N E n gl J M ed 2012;367:1237-44.
26. Tan EM, Feltkamp TE, Smolen JS et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997;40:1601-11.
27. EASLClinicalPracticeGuidelines. Wilson's disease. J Hepatol 2012;56: 671-85.
28. Kleiner DE, Chalasani N, Lee W et al. Hepatic histological f ndings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 2014; 59: 661-70.
29. Lewis JH, Kleiner DE. Hepatic injury due to drugs, chemicals and toxins. In: Burt AD, Portmann BC, Ferrell LD (eds), MacSween's Pathology of the Liver, 6th edn, Churchhill Livingstone Elsevier, Edinburgh, 2012, pp. 645-760.
30. Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl 2007; 13: 953-5.
31. Ichai P, Duclos-Vallee JC, Guettier C et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007;13:996-1003.
32. Kalb RE, Strober B, Weinstein G et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Derma-tol 2009;60:824-37.
33. Saag KG, Theng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.
34. Berends MA, vanOijen MG, Snoek J et al. Reliabilityofthe Roenigk classification of liver damage af er methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens. Arch Dermatol 2007;143:1515-9.
35. Bjornsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ter 2007;25:1411-21.
36. Rochon J, Protiva P, Seef LB et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008; 48: 1175-83.
37. Rockey DC, Seef LB, Rochon J et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010;51:2117-26.
38. Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol 2005;33:155-64.
39. Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a US multicenter, prospective study. Hepatology 2010;52: 2065-76.
40. Bernal W, Auzinger G, Dhawan A et al. Acute liver failure. Lancet 2010;376:190-201.
41. Ostapowicz GA, Fontana RJ, Schiodt FV et al. Resultsofa prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:945-54.
42. Cholongitas E, Teocharidou E, Vasianopoulou P et al. C o m p aris o n o f the Sequential Organ Failure Assessment Score with the King's College Hospital Criteria and the Model for End-Stage Liver Disease score for the prognosis of acetaminophen-induced acute liver failure. Liver Transpl 2012;18:405-12.
43. Rutherford A, King LY, Hynan LS, et al., ALF Study Group. Development of an accurate index for predicting outcomes of patients with acute liver failure. Gastroenterology 2012; 143: 1237-43.
44. Bechmann LP, Jochum C, Kocabayoglu P et al. Cytokeratin 18-based modi-fication of the MELD score improves prediction of spontaneous survival afer acute liver injury. J Hepatology 2010;53:639-47.
45. Papay JI, Clines D, Raf R et al. Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol 2009; 54: 84-90.
46. GuidanceforIndustry. Drug-induced liver injury: premarketing clinical evaluation. Food and Drug Administration, July 2009. http://www.fda.gov/ downloads/Drugs/./Guidances/UCM174090.pdf (Accessed on 16 October 2013).
47. Lee WM, Hynan LS, Rossaro L et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009;137:856-64.
48. Saliba F, Camus C, Durand F et al. Albumin dialysis with a noncell artif cial liver support device in patients with acute liver failure. Ann Intern Med 2013;159:522-31.
49. Squires RH, Dhawan A, Alonso E et al. Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. Hepatology 2013;57:1542-9.
50. Fontana RJ, Hayashi PH, Gu J et al. T ere is substantial morbidity and mortality associated with idiosyncratic drug induced liver injury: results from the DILIN prospective study. Gastroenterology; advance online publication, 27 March 2014 (e-pub ahead of print).
51. !http://www. fda.gov/Food/DietarySupplements/default.htm; Accessed on 6 April 2013.
52. !http://www. fda.gov/food/foodsafety/product-specif cinformation/ medicalfoods/default.htm; Accessed 4 August 2013.
53. Chalasani N, Vuppalanchi R, Navarro VJ et al. Acute liver injury due to Flavocoxid (limbrel), a medical food for osteoarthritis. A case series. Ann Intern Med 2013;156:857-60.
54. !http://www. fda.gov/Food/DietarySupplements/ GuidanceComplianceRegulatoryInformation/default.htm; Accessed 6 April 2013.
55. USDepartmentofHealthandHumanServicesOfceofInspectorGeneral, AdverseEventReportingforDietarySupplements:AnInadequateSafetyValve, OEI-01-00-00180(Washington, D.C.: April 2001).
56. Komes D, Belscak-Cvitanovic A, Horzic D et al. Phenolic composition and antioxidant properties of some traditionally used medicinal plants affected by the extraction time and hydrolysis. Phytochem Anal 2011;22: 172-80.
57. Scheepmaker MM, Gower NT. The quality of selected South African and international homoeopathic mother tinctures. Afr J Tradit Complement Altern Med2011;8 (5 Suppl): 46-52.
58. Sundaresan V, Sahni G, Verma RS et al. Impact of geographic range on genetic and chemical diversity of Indian valerian (Valeriana jatamansi) from northwestern Himalaya. Biochem Genet 2012;50:797-808.
59. Xiao WL, Motley TJ, Unachukwu UJ et al. Chemical and genetic assess ment of variability in commercial Radix Astragali (Astragalus spp) by ion trap LC-MS and nuclear ribosomal DNA barcoding sequence analyses. J Agric Food Chem 2011;59:1548-56.
60. Fleshler N, Harvey M, Adomat H et al. Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors. J Urol 2005;174:636-41.
61. Kneifel W, Czech E, Kopp B. Microbial contamination of medicinal plants. Planta Med 2000;68:5-15.
62. Stickel F, Droz S, Patsenker E et al. Severe hepatotoxicity following ingestion of Herbalife contaminated with Bacillus subtilis. J Hepatol 2009;50:111-7.
63. Ernst E. Heavy metals in traditional Indian remedies. Eur J Clin Pharmacol 2002;57:891-6.
64. Saper RB, Phillips RS, Sehgal A et al. Lead, mercury, and arsenic in US-and Indian-manufactured Ayurvedic medicines sold over the internet. JAMA 2008;300:915-23.
65. Blendon RJ, DesRoches CM, Benson JM et al. Americans' views on the use and regulation of dietary supplements. Arch Intern Med 2001;161:805-10.
66. Ishak KG. Hepatic lesions caused by anabolic and contraceptive steroids. Semin Liver Dis 1981;1:116-28.
67. Haupt HA, Rovere GD. Anabolic steroids a review of the literature. Am J Sports Med 1984;12:469-84.
68. Elsharkawy AM, McPherson S, Masson S et al. Cholestasis secondary to anabolic steroid use in young men. BMJ 2012; 34: 4e468.
69. Weston CFM, Cooper BY, Davies JE et al. Veno-occlusive disease of the liver secondary to ingestion of comfrey. Br Med J 1987;295:183.
70. Bras G, Jelife DB, Stuart KL. Veno-occlusive disease of the liver with non-portal type of cirrhosis occurring in Jamaica. AMA Arch Pathol 1954;57:285-300.
71. Chojkier M. Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizi-dine alkaloids. J Hepatol 2003;3:437-46.
72. Stillman AE, Huxtable RJ, Consroe P et al. Hepatic veno-occlusive disease due to pyrrolizidine (Senecio) poisoning in Arizona. Gastroenterology 1977;73:349-52.
73. Mohabbat O, Srivastava RN, Younos MS et al. An outbreak of hepatic veno-occlusive disease in North-Western Afghanistan. Lancet 1976;2:271-6.
74. Tandon BN, Tandon RK, Tandon HD et al. An epidemic of veno-occlusive disease in Central India. Lancet 1976;2:271-2.
75. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part 1: overall and upper gastrointestinal diseases. Gastroenterology 2009;136:376-86.
76. Lucado J, Paez K, Eixhauser A. Medication-related adverse outcomes in US Hospitals and Emergency Departments, 2008. Agency for Healthcare Research and Quality, Statistical brief #109, http://www.hcup-us.ahrq. gov/reports/ statbriefs/sb109.pdf (accessed on 21 May 2014).
77. Galan MV, Potts JA, Silverman AL et al. The burden of acute non-fulminant drug-induced hepatitis in a United States tertiary referral center. J Clin Gastroenterol 2005;39:64-7.
78. Vuppalanchi R, Liangpunsakul S, Chalsani N. Etiology of new-onset jaun-dice: how of en is it caused by idiosyncratic drug-induced liver injury in the United States. Am J Gastroenterol 2007;102:558-62.
79. Fontana RJ, Seef LB, Andrade RJ et al. Standardization of nomenclature and Causality Assessment in Drug-Induced liver Injury: Summary of a Clinical Research Workshop. Hepatology 2010; 52: 730-42.
80. Chalasani N, Younossi Z, Levine JE et al. The diagnosis and management of non-alcoholic fatty liver: Practice guideline by the American Association of the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterology Association. Am J Gastroenterol 2012;107:811-26.
81. Ghany MG, Nelson DR, Strader DB et al. An update on treatment of Genotype 1 chronic hepatitis C virus infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-43.
82. Lewis JH, Stine JG. Prescribing medications in patients with cirrhosis-a practical guide. Aliment Pharmacol Ter 2013;37:1132-56.
83. Chalasani N, Aljadhey H, Kesterson J et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;128:1287-92.
84. Vuppalanchi R, Teal E, Chalasani N. P atien ts w ith elevated b aselin e liver en-zymes do not have higher frequency of hepatotoxicity form lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005;329:62-5.
85. Lewis JH, Mortensen ME, Zweig S et al. E f cacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled multicenter trial. Hepatology 2007;46:1453-63.
86. Osman KA, Osman MM, Ahmed MH. Tamoxifen-induced nonalcoholic steatohepatitis: where are we now and where are we going? Expert Opin Drug Saf 2007;6:1-4.
87. Whiting-O'Keefe QE, Fyfe KH, Sack KD. M eth o trexate an d h isto lo gical hepatic abnormalities: A meta-analysis. Am J Med 1991;90:711.
88. Cohen DE, Anania FA, Chalasani N. A n assessm en t o f statin safety b y hepatologists. Am J Cardiol 2006;97:78-84.
89. Athyros VG, Tziomalos K, Gossios TD et al. Safety and ef cacy of longterm statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-22.
90. Bader T, Hughes LD, Fazili J et al. A randomized controlled trial adding f uvastatin to peginterferon and ribavirin for na ï ve genotype 1 hepatitis C patients. J Viral Hepatitis 2013;20:622-7.
91. Sulkowski MS, Tomas DL, Chaisson RE et al. Hepatotoxicity associated with antiretroviral therapy in adults with human immunodef ciency virus and the role of hepatitis C or B virus infection. JAMA 2000;283: 74-80.
92. Nunez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010; 52: 1143-55.
93. Ungo JR, Jones D, Ashkin K et al. Anti-tuberculosis drug-induced hepato-toxicity: the role of hepatitis C virus and the HIV. Am J Resp Crit Care Med 1998;157:1871-6.
94. Wong WM, Wu PC, Yuen MF et al. Anti-tuberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000;31:201-6.
95. Sembera S, Lammert C, Talwalkar JA et al. Frequency, clinical presentation, and outcomes of drug-induced liver injury af er liver transplantation. Liver Transpl 2012; 18: 803-10.
96. Vento S, Garofano T, Renzini C et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Eng J Med 1998;338:286-90.
97. Hennes EM, Zeniya M, Czaja AJ et al. Si m p l if ed criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-76.
98. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001; 33: 308-10.
99. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005;4:489-99.